In response to market manipulation driven by companies in Indonesia, Laos, and India, the petitions were filed by The Alliance for American Solar Manufacturing and Trade.
The Senate’s decision to remove the FEOC Excise Tax and weaken FEOC restrictions is a blatant giveaway to the Chinese Communist Party’s solar industry.
Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
CPA warned that the Senate version of President Trump’s reconciliation bill—known as the One Big Beautiful Bill—contains a critical loophole in both the Section 48E investment tax credit and 45Y production tax credit in the Inflation Reduction Act (IRA), creating an unintended but dangerous giveaway to China’s solar industry.
The President’s tariff increase comes at a critical moment, reflecting a clear understanding of the ongoing threats faced by the U.S. aluminum and steel industry, particularly from heavily subsidized foreign competitors.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
CPA’s submission documents how the domestic trucking sector underpins U.S. commerce, and that ensuring a domestic industrial base for producing these trucks is vital to military readiness and civil emergency response.
As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.
While CPA recognizes certain positive elements of the deal — including a historic pivot towards prioritizing tariff revenue as well as industrial protection — it remains concerned about dangerous precedents being set by sacrificing domestic production while pursuing foreign market access.
